期刊文献+

蛋白结合类尿毒症毒素蛋白结合率方法测定 被引量:3

Determination of plasma protein binding rate of protein binding uremic toxins
下载PDF
导出
摘要 目的建立蛋白结合类尿毒症毒素蛋白结合率的检测方法,测定慢性肾脏病(chronic kidney disease,CKD)患者血清马尿酸(hippuric acid,HA)、硫酸吲哚酚(indoxyl sulfate,IS)、硫酸对甲酚(p-cresyl sulfate,PCS)及3-羧基-4-甲基-5-丙基-2-呋喃丙酸(3-carboxy-4-methyl-5-propyl-2-furan-propionic acid,CMPF)4种蛋白结合类尿毒症毒素的蛋白结合率。方法通过对方法的专属性、线性关系、精密度等考察,验证超滤法联合高效液相色谱-串联质谱法(high performance liquid chromatagraphy-tandem mass spectrometry,HPLC-MS/MS)测定蛋白结合类尿毒症毒素的游离浓度的可行性,并采用该方法测定CKD患者血清HA、IS、PCS、CMPF的蛋白结合率。结果内源性干扰物质在待测物的出峰位置基本不干扰HA、IS、PCS、CMPF的测定;本方法在10-1 000 ng/ml(IS、PCS、CMPF)、50-5 000 ng/ml(HA)范围内线性良好;日内精密度为0.84%,日间精密度为1.18%;超滤膜回收率均〉95%;健康对照组HA、IS、PCS及CMPF的蛋白结合率为(83.44±3.04)%、(98.73±0.55)%、(98.42±0.95)%、(96.66±2.65)%;CKD 3-5期HA、IS、PCS及CMPF的蛋白结合率依次为3期(79.72±3.82)%、(99.18±0.45)%、(98.64±0.64)%、(95.89±3.52)%;4期(71.09±7.66)%、(98.24±0.95)%、(98.26±0.73)%、(91.82±5.10)%;5期(61.22±7.62)%、(97.41±1.10)%、(96.85±1.51)%、(97.51±1.52)%。结论所建立的方法灵敏度高,专属性和重复性好,操作简单,能够满足定量分析测试要求。HA蛋白结合率均〉60%,与HSA之间具有中等强度结合,IS、PCS及CMPF的蛋白结合率均〉90%,与HSA之间具有高强度结合。 Objective To detect the serum albumin binding rate of protein binding uremic toxins, and then detect the serum albumin binding rate of hippuric acid (HA), indoxyl sulfate (IS), p-cresyl sulfate (PCS) and 3-carboxy-4-methyl-5-propyl-2-furan-propionic acid (CMPF) in chronic kidney disease (CKD) patients. Methods This method was inspected through specificity, linearity and precision, validation the feasibility of ultrafiltration method which combined with high performance liquid chromatagraphy-tandem mass spectrometry (HPLC-MS/MS) to detect free concentration of protein-bound uremic toxins, and to detect the serum albumin binding rate of HA, IS, PCS and CMPF in CKD patients. Result Endogenous interfering substances had little interference in the peak position of HA, IS, PCS, and CMPF when they were detected. The liner was good with 10-1 000 ng/ml of IS, PCS CMPF and 50-5 000 ng/ml of HA; days of precision was 0.84%, while daytime precision was 1.18%; ultrafiltration membrane recovery was above 95%; the protein binding rates of HA, IS, PCS and CMPF in healthy controls were (83.44±3.04)%, (98.73±0.55)%, (98.42±0.95)%, (96.66±2.65)%, which were (79.72±3.82)%, (99.18±0.45)%, (98.64±0.64)%, (95.89±3.52)% in CKD stage 3, and (71.09±7.66)%, (98.24±0.95)%, (98.26±0.73)%, (91.82±5.10)% in CKD stage 4, and (61.22±7.62)%, (97.41±1.10)%, (96.855±1.51)%, (97.515±1.52)% in CKD stage 5, respectively. Conclusion The method which has high sensitivity, good specificity and reproduction can satisfy the requirement of quantitive analysis. The protein conjugation rate of HA was more 60%, which was middle degree with human serum albumin (HSA) while the binding of IS, PCS and CMPF were more than 90%, which had high degree with HSA
出处 《空军医学杂志》 2015年第5期284-287,298,共5页 Medical Journal of Air Force
关键词 慢性肾脏病 蛋白结合类尿毒症毒素 蛋白结合率 超滤法 Chronic kidney disease Protein-bound uremic toxin Protein binding rate Ultrafiltration
  • 相关文献

参考文献12

  • 1Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of uremia toxins[J]. J Am Soc Nephrol, 2008, 19 (5) .. 863-870.
  • 2吴阳,张英丰.超滤法测定脱水穿心莲内酯的血浆蛋白结合率[J].中国实验方剂学杂志,2011,17(21):57-59. 被引量:12
  • 3Itoh Y, Ezawa A, Kikuchi K, et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production[J]. Anal Bioanal Chem, 2012, 403 (7) : 1 841-1 850.
  • 4Ohtsuki S, Asaba H, Takanaga H, et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux ofindoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain[J]. J Neurochem, 2002, 83 (1): 57-66.
  • 5Meijers BK, Van Kerckhoven S, Verbeke K, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage[J]. Am J Kidney Dis, 2009, 54 (5) : 891-901.
  • 6Thomas G, Jaber BL. Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence[J]. Semin Dial, 2009, 22(6) : 610-614.
  • 7Jourde Chiche N, Dou L, Sabatier F, et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients[J]. J Thromb Haemost, 2009, 7 (9) : 1 576-1 584.
  • 8Iwasaki Y, Kazama JJ, Yamato H, et al. Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease[J]. Bond, 2013, 57 (2) : 477-483.
  • 9Palm F, Nangaku M, Fasehing A, et al. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress[J]. Am JPhysiol Renal Physiol, 2010, 299 (2) : 380-386.
  • 10Krieter DH, Haeld A, Rodriguez A, et al. Protein-bound uraemic toxin removal in haemodialysis and post dilution haemodiafiltration[J]. Nephml Dial Transplant, 2010, 25 (1) : 212-218.

二级参考文献6

共引文献11

同被引文献48

  • 1Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidne3disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
  • 2Go AS,Chertow GM,Fan D,et al.Chronic kidney disease and therisks of death,cardiovascular events,and hospitalization[J].N Engl J Med,2004,351(13):1296-1305.
  • 3Itoh Y,Ezawa A,Kikuchi K,et al.Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production[J].Anal Bioanal Chem,2012,403(7):1841-1850.
  • 4Meijers B,Toussaint ND,Meyer T,et al.Reduction in ProteinBound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis[J].Am J Nephrol,2011,34(3):226-232.
  • 5Lin CJ,Liu HL,Pan CF,et al.Lndoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease[J].Arch Med Res,2012,43(6):451-456.
  • 6Palm F,Nangaku M,Fasching A,et al.Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress[J].Am J Physiol Renal Physiol,2010,299(2):380-386.
  • 7Liabeuf S,Barreto DV,Barreto FC,et al.Free p-cresyl sulphate is a predictor of mortality in patients at different stages of chronic kidney disease[J].Nephrol Dial Transplant,2010,25(4):1 183-1 191.
  • 8Eknoyan G,Beck GJ,Cheung AK,et al.Effect of dialysis dose and membrane flux in maintenance hemodialysis[J].N Engl J Med,2002,347(25):2 010-2 019.
  • 9Meyer TW,Leeper EC,Bartlett DW,et al.Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes[J].J Am Soc Nephrol,2004,15(2):1927-1935.
  • 10Tao X,Thijssen S,Levin N,et al.Enhanced Indoxyl Sulfate Dialyzer Clearance with the Use of Binding Competitors[J].Blood Purif,2015,39(4):323-330.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部